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(Received for publication, July 26, 1984, and in revised form, November 26, 1984) 
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The domain structure of human fibronectins isolated 
from plasma and  from  the conditioned medium of nor- 
mal and  transformed  fibroblasts  was analyzed by  lim- 
ited proteolysis and  S-cyanylation followed by  immu- 
nostaining of released fragments with five kinds of 
antibodies, each specific for one functional domain. 
The  results  indicate that  all  three human fibronectins 
are composed of the same set of functional domains 
aligned in  the same topological order. However, the 
following clear  differences  were found in specific frag- 
ments released from plasma fibronectin (pFN) and 
those released from  fibronectin of normal (N-cFN) and 
transformed fibroblasts (T-cFN). (i) Two fragments 
(M, = 70,000 and 60,000) were released from the 
COOH-terminal region of pFN by cathepsin D. These 
fragments  represent  the COOH-terminal heparin- 
binding (Hep-2) and fibrin-binding (Fib-2) domains. 
The  corresponding  fragments released from both N- 
cFN and T-cFN by cathepsin D had much larger mo- 
lecular weights (Mr = 100,000 and 83,000-74,000) 
than those from pFN. The  fragments from the F i b 2  
domain alone, however, did not show any  difference 
among all  three FNs. (ii)  The  internal  region,  from  the 
gelatin-binding (Gel) domain through the Hep-2 do- 
main, of N-cFN and T-cFN was released as a M, = 
210,000 fragment upon mild trypsin digestion. The 
corresponding  fragment  from pFN was released as a 
M,= 185,000 fragment.  (iii)  The COOH-terminal half, 
including  the Hep-2 domain, of both N-cFN and T-cFN 
was released by S-cyanylation as M, = 160,000- 
145,000 fragments, which are 25,000-20,000 larger 
than  the  corresponding  fragments of pFN. These re- 
sults  clearly  indicate that  the Hep-2 domain of N-cFN 
and T-cFN is 30,000-20,000 daltons larger  than  the 
same domain of pFN. 
Although various fragments released from N-cFN 
and T-cFN showed a similar  pattern,  there  were minor 
differences. (i) Thermolysin fragments derived from 
the Hep-2 domain of N-cFN were  clearly distinguish- 
able from those from T-cFN. Three groups of frag- 
ments  with M, = 40,000, 35,000-32,000, and 30,000 
were released from N-cFN, while only the 35,000- 
32,000 fragment  was released from T-cFN. (ii)  The M, 
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= 44,000/60,000 thermolysin fragments  representing 
the Gel domain and  the M, = 210,000/165,000 tryptic 
fragments  representing  the  internal domains of T-cFN 
were  slightly,  but consistently, larger  than those of N- 
cFN. 
A panel of domain-specific antibodies combined with 
well-characterized proteolytic and chemical fragmen- 
tation  provides  a highly sensitive  and specific proce- 
dure to  study  the domain structure of various  types of 
fibronectins. This procedure requires only a small 
quantity of protein, without prior  purification,  and  is 
applicable to both soluble and insoluble fibronectins. 
Fibronectins  are a group of high  molecular  weight  adhesive 
glycoproteins present in extracellular matrices and plasma 
(reviewed in Refs. 1-8). FNs’ are produced by many types of 
cultured cells including fibroblasts, epithelial  and  endothelial 
cells,  myoblasts, glial cells, and macrophages (1-8). Oncogenic 
transformation of these cells causes a marked decrease in  the 
biosynthesis of FN and its deposition in the extracellular 
matrix (9-11). 
FNs isolated from  plasma  and from  cells in  culture  are very 
similar  in  their chemical, biological, and immunological prop- 
erties,  yet  there  are  clear differences  between them  in  subunit 
size (12, 13), carbohydrate structure (14-16), disulfide-de- 
pendent polymerization (17-19), solubility  (17), ability to 
agglutinate sheep erythrocytes (12), and ability to  restore 
normal  fibroblast morphology to  transformed cells (12). FNs 
produced by transformed cells may also be different from 
those produced by normal cells (20, 21). The basis for the 
molecular and functional polymorphism of FNs is poorly 
understood. 
FNs  are composed of multiple  domains which differ in  their 
biological activities (reviewed in Refs. 1-8). These domains 
can be separated by limited proteolysis and  subsequent  affin- 
The abbreviations used are: FN, fibronectin; pFN, plasma fibro- 
nectin; cFN, cellular fibronectin; N-cFN, cellular fibronectin pro- 
duced by normal fibroblasts; T-cFN, cellular fibronectin produced by 
transformed fibroblasts; Hep-IIFib-I, the NH2-terminal domain that 
binds to heparin and fibrin; Gel, the gelatin-binding domain; Cell/ 
Hep-2, the cell- and heparin-binding domain which can be further 
separated into Cell and Hep-2 domains, which represent the  NHz- 
terminal and COOH-terminal regions of the Cell/Hep-2 domain, 
respectively; Fib-2, the COOH-terminal fibrin-binding domain; 
CAPS, cyclohexylaminopropane sulfonic acid; BSA, bovine serum 
albumin; SDS, sodium dodecyl sulfate; PBS, 8.1 mM Na2HPOI, 1.5 
mM KHzPOI, 137 mM NaC1,  2.7 mM KC], pH 7.4, sc, the S-cyanyla- 
tion-cleaved fragments. 
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FIG. 1. Proposed model for the 
proteolytic and chemical fragmen- 
tation of plasma fibronectin. Frag- 
mentation pathways of pFN by limited 
proteolysis with thermolysin ( A ) ,  trypsin 
( B ) ,  and cathepsin D (C), and by S -  
cyanylation (D) are schematically pre- 
sented based on previous reports (Refs. 
22, 23, 33, 34, 36, 48) and the results 
reported here. The nomenclature of the 
functional domains is taken from Refs. 
22 and 49. The molecular weights of 
cathepsin  D fragments are based on the 
present study and are slightly different 
from the previous reports by Richter et 
al. (23, 48). The location of the Fib-2 
domain within the tryptic 37K fragment 
is tentative. The arrowheads indicate the 
major  cleavage sites. 
ity chromatography using different ligands. For example, hu- 
man plasma FN  can be  cleaved into at least four functionally 
distinct fragments with M, = 155,000-145,000 (Cell/Hep-2 
domain), 44,000 (Gel domain), 24,000 (Hep-I/Fib-I domain), 
and 22,000 (Fib-2 domain) by  mild thermolysin digestion (22) 
(also see  Fig. 1). The domain structure of FNs produced by 
cells in culture is, however, less well-characterized than  that 
of pFN. Comparison of the domain structure of different FNs 
may provide a molecular basis for understanding  FN poly- 
morphism. In an extensive comparative study (37) of the 
domain structure of chicken FNs, thermolysin fragments of 
pFN and cFN separated by various affinity columns were 
compared. In another study (38), differences between pFN 
and cFN in the COOH-terminal domain were suggested by a 
monoclonal antibody which reacts preferentially with cFN. 
In our previous study (33), we developed a highly sensitive 
and specific procedure for the analysis of the domain structure 
of FNs using a panel of antibodies specific for each functional 
domain. The method is now applied to three human FNs 
isolated from plasma and from the culture  supernatants of 
normal and  transformed fibroblasts, which were cleaved by 
limited proteolysis with thermolysin, trypsin,  and  cathepsin 
D as well as by S-cyanylation, followed by identification of 
each domain with specific antibodies. The fragmentation  pat- 
terns of human pFN by these treatments have been well- 
characterized (13, 22-24, 33-37) and  are  illustrated  schemat- 
ically in Fig. 1. The results indicate that  the COOH-terminal 
heparin-binding domain, Hep-2, of both N-cFN and  T-cFN 
is significantly larger than  the same domain of pFN. A signif- 
icant difference in the fragments derived from the Hep-2 
domain and from the gelatin-binding domain between N-cFN 
and  T-cFN  has also been demonstrated by this new procedure. 
EXPERIMENTAL  PROCEDURES 
Purification of FNs-Plasma FN was purified from human plasma 
by gelatin-Sepharose affinity chromatography as previously described 
(22) and further purified by heparin-Sepharose Chromatography. pFN 
bound to heparin-Sepharose was eluted with PBS supplemented with 
0.5 M NaCl, dialyzed against 2 mM CAPS, 0.5 mM EDTA (pH l l ) ,  
and stored at -85 "C. The pFN thus purified was found to contain  a 
trace  amount of the tryptic 32K fragment' which  was detectable by 
immunostaining with anti-Hep-l/Fib-l antibodies. The contaminant 
fragment came from the heparin-Sepharose, which had been used for 
the purification of the tryptic 32K fragment. cFNs produced by 
normal human lung fibroblasts WI-38 and  their SV-40 transformants 
WI-38/VA13 were isolated from the conditioned culture medium as 
follows. Cells were grown in Dulbecco's modified Eagle's medium 
containing 5% fetal calf serum which had been depleted of bovine 
pFN by passing through a large capacity gelatin-Sepharose column 
twice. After the cells became confluent, fetal calf serum in the medium 
was replaced with a mixture of growth hormones including epidermal 
growth factor (1 ng/ml), insulin (4 pg/ml), transferrin (2.5 pg/ml), 
and bovine serum albumin (0.1 mg/ml) to avoid possible contamina- 
tion of bovine FN. Approximately 4 liters of conditioned medium 
were harvested from 40 plastic roller bottles (Falcon No.  3027)  every 
2 days, clarified by centrifugation at 10,000 X g for 15 min, and 
applied to a gelatin-Sepharose column (40 ml of bed volume) equipped 
with a precolumn of underivatized Sepharose. The gelatin-Sepharose 
column was washed sequentially with PBS containing 1 mM phenyl- 
methylsulfonyl fluoride and 0.5 mM EDTA, PBS supplemented with 
0.5 M NaCl, and  PBS containing 0.8 M urea. Bound FNs were eluted 
with PBS containing 6 M urea, dialyzed against 2 mM CAPS, 0.5 mM 
EDTA (pH 11) unless otherwise stated,  and stored at -85 "C. The 
protein concentration of purified FNs was estimated spectrophoto- 
metrically by assuming that  the absorption coefficient of 0.1% protein 
solution at 280 nm is 1.28 cm" (50). FNs thus purified from the 
condition medium contained  a variable amount of contaminant pro- 
teins as judged from the protein-staining patterns of these FNs after 
SDS-polyacrylamide gel electrophoresis. Since these contaminants 
do not affect the immunoblot analysis, these  FNs were used without 
further purification. 
Fragmentation of FNs-Thermolysin and trypsin digestion of FNs 
' 32K, 155K, 145K fragments, etc., fragments with M ,  = 30,000, 
155,000, 145,000, etc. 
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was performed as described previously (22). Cathepsin  D digestion 
was performed according to Richter et al. (23). S-Cyanylation was 
carried out using 2-nitro-5-thiocyanobenzoic acid as described previ- 
ously (24). Detailed fragmentation conditions are described in the 
legend for each figure. 
Subfragmentation of the Thermolysin 155K and 145K Fragments- 
The thermolysin-cleaved 155K/145K fragments were purified by 
DEAE-cellulose chromatography as described previously (13). The 
purified 155K/145K fragments (3.6 mg) were further digested with 
thermolysin at  an increased protease  concentration (15 pg/ml) in 2.7 
ml of 25 mM Tris.Cl  (pH 7.6) containing 0.5 mM EDTA, 135 mM 
NaCl, 2.5 mM CaClz at  22 "C for 4 h. Digestion was terminated by 
the addition of EDTA to give a  final  concentration of 5 mM. The 
digest was applied to a heparin-Sepharose column (bed volume, 4 ml) 
equilibrated with 25 mM Tris-C1  (pH 7.6) containing 0.5 mM EDTA 
and 135 mM NaC1. The bound fragments were eluted with 25 mM 
Tris buffer containing 1 M NaCl. The unbound and bound fragments 
were separately dialyzed against  10 mM Tris-C1  (pH 7.6) containing 
0.5 mM EDTA, lyophilized, and analyzed by SDS-polyacrylamide gel 
electrophoresis. 
Domain-specific  Antibodies-Antibodies directed to  Hep-l/Fib-I, 
Gel, and Fib-2 were raised in New Zealand white rabbits by immuni- 
zation with purified domain fragments, ie.,  the tryptic 32K fragment 
(22) for Hep-l/Fib-l domain, the thermolysin-cleaved 44K fragment 
(13) for Gel domain, and  the thermolysin 22K fragment (13) for Fib- 
2 domain. These  fragments were purified as described (13,  22) and 
further purified by preparative gel electrophoresis. Two monoclonal 
antibodies directed to human  pFN, IST-1  and IST-4, were obtained 
as previously described (25, 26). 
SDS-Polyacrylamide Gel Electrophoresis and Immunoblots-Pro- 
teolytic or S-cyanylation-cleaved fragments were separated  on 9.5% 
SDS-polyacrylamide gels by the method of Laemmli (27). Samples 
were reduced with 2% 2-mercaptoethanol. Gels were either directly 
stained with Coomassie blue or subjected to electrotransfer of the 
fragments to nitrocellulose sheets according to Towbin et al. (28). 
After the transfer of proteins, the nitrocellulose sheets were stained 
with 0.1% Fast green (29) to visualize proteins, then blocked with 2% 
BSA, and immunostained with domain-specific antibodies and lz5I- 
protein  A as previously described (30). When monoclonal antibodies 
were used, the nitrocellulose sheets were incubated with rabbit anti- 
mouse immunoglobin antibodies between the incubation with primary 
antibodies and '251-protein A. The nitrocellulose sheets were then 
washed with PBS containing 0.05% Triton X-100, briefly blotted 
with paper towels, and exposed to Kodak XAR-5 X-ray films. 
Materials-Thermolysin, cathepsin D, pepstatin A, gelatin, soy- 
bean trypsin inhibitor, BSA (Fraction V), transferrin, and insulin 
were obtained from Sigma; trypsin was from Worthington; epidermal 
growth factor was from Collaborative Research (Lexington, MA); 
rabbit  antimouse immunoglobulin antibodies  (light and heavy chains 
specific) was from Cappel Laboratories (Cochranville, PA); 2-nitro- 
5-thiocyanobenzoic acid was from Eastman Kodak; NalZ5I was from 
New England Nuclear; ultra pure urea was from Schwarz/Mann 
(Orangeburg, NY). Gelatin-Sepharose was prepared according to 
Cuatrecasas and Anfinsen (31). Iodination of protein A was performed 
by a  chloramine-T method (32). Heparin-Sepharose was a generous 
gift of Dr. Kazuo Fujikawa (Department of Biochemistry, University 
of Washington). 
RESULTS 
Domain Specificities of Antibodies 
Three polyclonal and two monoclonal antibodies were used 
as specific probes for four functionally distinct FN domains: 
Hep-l/Fib-1, Gel, Cell/Hep-2, and Fib-2 (summarized in  Table 
I). Two monoclonal anti-FN antibodies, IST-1 and IST-4, 
were found to recognize different regions of the Cell/Hep-2 
domain (Fig. 2). Among the fragments of pFN cleaved  by S- 
cyanylation, IST-1 bound to sc135K and sc125K fragments, 
whereas IST-4 bound to  the scl6OK fragment (Fig. 2). The 
former fragments (i.e., sc135K and sc125K) were derived from 
the COOH-terminal halves of a! and p subunits of pFN, 
whereas the  latter fragment was derived from the  NH2-ter- 
TABLE I 
Summary of the domain-specific antibodies used in the present study 
Antibodies Domain Polyclonal/ Antigen used 
specificity monoclonal for immunization 
Anti-Hep-I/Fib-I Hep-1/Fib-I Polyclonal Tryptic 32K" 
Anti-Gel Gel Polyclonal Thermolysin- 
IST-4 
IST-1 Hep-2 Monoclonal pFN 
cleaved  44Kb 
Cell Monoclonal pFN 
Anti-Fib-2 Fib-2 Polyclonal Thermolysin- 
cleaved  22Kb 
Prepared as described in Ref. 22. 
Prepared  as described in Ref.  13. 
A C 
1 2   1 2  1 2  
FIG. 2. Domain specificity of two monoclonal antibodies, 
IST-1 and IST-4. The binding specificity of two  monoclonal anti- 
human pFN antibodies, IST-1  and IST-4, was examined using ther- 
molysin fragments (lane I) and S-cyanylation-cleaved fragments (lane 
2) of pFN by immunoblots. A, protein staining; B and C, immuno- 
staining with IST-1  and IST-4, respectively. The pFN used here was 
dialyzed against  10 mM Tris.Cl  (pH 7.6) containing 0.5 mM EDTA 
and 50 mM NaCl instead of 2 mM CAPS buffer, pH 11. pFN (1.0  mg/ 
ml) was digested with thermolysin (2.5  pg/ml) for 2  h at 22  "C. The 
enzyme/substrate ratio was thus 1:400. S-Cyanylation was performed 
as described under "Experimental Procedures." The apparent molec- 
ular weights of the fragments of interest  are shown in the margin. 
minal half  (33, 34) (also see below). IST-1 also bound to 40K 
and 30K thermolysin fragments in addition to the 155K/145K 
(Fig. 2B). In contrast,  IST-4 recognized a 105K fragment, but 
not  the 40K nor 30K fragments (Fig. 2C). This indicates that 
the 40K and 30K fragments originated from the COOH- 
terminal region of the Cell/Hep-2 domain, which is considered 
to be the heparin-binding domain. 
In support of this conclusion, purified 155K/145K frag- 
ments were further degraded into 105K,  40K, and 30K frag- 
ments upon prolonged thermolysin digestion (Fig. 3A, lane 1). 
Fractionation of these fragments on heparin-Sepharose indi- 
cated that  the 40K and 30K fragments were capable of binding 
to heparin, but that  the 105K fragment was not (Fig. 3A, lanes 
2 and 3). IST-1 selectively bound to  the heparin-binding 40K 
and 30K fragments (Fig. 3B), confirming that  IST-1 is di- 
rected to  the Hep-2 domain located at the COOH-terminal 
region of the Cell/Hep-2 domain. In contrast,  IST-4 bound to 
the heparin-unbound 105K fragment, which is considered to 
be derived from the NH2-terminal portion of the Cell/Hep-2 
domain, i.e., the Cell domain. Specificities of IST-1  and  IST- 
4 were further confirmed by the binding of these antibodies 
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FIG. 3. Subdivision of the 155K/145K thermolysin frag- 
ments. The purified 155K/145K fragments were cleaved further by 
thermolysin using an increased enzyme concentration (15 pg/ml). 
The digest was fractionated  on  a  heparin-Sepharose column as de- 
scribed under  “Experimental Procedures.” The unfractionated digest 
(lune I ) ,  heparin-unbound fragments (lune 2), and heparin-bound 
fragments (lane 3) were analyzed by immunoblots. A,  protein  staining 
of the gel; B and C, immunostaining with IST-1  and IST-4, respec- 
tively. Molecular weights of the standard proteins (A, lane S)  are 
shown in the left margin. A small amount of the 145K fragment 
remained undigested under  these conditions. 
to  the  cathepsin D fragments of the  three different FNs  as 
described below. 
Comparison of Domain Structure of pFN, N-cFN, and 
T-cFN by Limited Proteolysis and S-Cyanylation 
Thrmolysin Digestion-Thermolysin has been shown to 
dissect FNs  into  their constitutive  domains (13, 22, 35) (also 
see Fig. lA). Fig. 4 shows the thermolysin digestion patterns 
of pFN, N-cFN, and T-cFN.  Fragments  containing  each do- 
main were identified by immunostaining  with domain-specific 
antibodies (Fig. 4, B-F). The  Hep-l/Fib-1 domain of all three 
FNs was released as a 24K fragment and its 27K precursor 
(Fig. 4B). These fragments were qualitatively identical irre- 
spective of the  FN type. The Gel domain of these  FNs was 
obtained as a 44K fragment and its 60K precursor (Fig. 4C); 
however, the 44K/60K fragments of N-cFN were slightly 
smaller t h m  those of pFN (Fig. 4C, lanes 4-6). In  contrast, 
the 44K/60K fragments of T-cFN were consistently slightly 
larger than  those of pFN. The Fib-2  domain was released as 
the same 22K fragment from all three  FNs (Fig. 4F), although 
immunostaining of this fragment from T-cFN was consist- 
ently weaker than  that from N-cFN or pFN. These results 
indicate that pFN, N-cFN, and  T-cFN consist of the same 
Hep-l/Fib-1, Gel, and Fib-2  domains,  although the Gel domain 
of T-cFY is slightly larger than  that of N-cFN or pFN. 
In  contrast,  the Cell/Hep-2 domain of pFN, N-cFN, and T- 
cFN gave similar, yet significantly different,  fragments upon 
thermolysin digestion. The CelllHep-2 domain of pFN was 
released as 175K and 145K fragments after brief thermolysin 
digestion (Fig. 4, D and E, lane 4 ) .  The 175K fragment 
contained both Cell/Hep-2 and Fib-2 domains and subse- 
quently degraded into 155K (Cell/Hep-2) and 22K (Fib-2) 
fragments (Fig. 4, D and  F, lanes 7 and 10). The 155K and 
145K fragments were further degraded into a 105K fragment 
(reactive with IST-4)  and 40K/30K fragments  (reactive with 
IST-1)  as shown in Fig. 3. 
The Cell/Hep-2 domain of N-cFN and T-cFN, however, 
was released as 155-160K fragment(s) upon brief thermolysin 
digestion (Fig. 4, D and  E, lanes 5 and 6). These  fragments 
were further degraded into a 105K fragment reactive with 
IST-4 (Fig. 40,  lanes 8, 9, 11, and  12)  and multiple 30-40K 
fragments reactive with IST-1 (Fig. 4E, lanes 8, 9, 11, and 
12). The 105K fragment of T-cFN was slightly larger than 
the 105K fragment of N-cFN. 
A clearer difference among pFN, N-cFN, and  T-cFN was 
found in  the 30-40K Hep-,%derived fragments reactive with 
IST-1. The Hep-2 domain of N-cFN gave three distinct frag- 
ments, 40K, 35-32K3, and 30K  (Fig. 4E, lane 11). The 35-32K 
fragment gave a broad band upon immunostaining with IST- 
1. In  contrast,  the Hep-2 domain of T-cFN gave only the 35- 
32K fragment, but  not  the 40K or 30K fragments (Fig. 4E, 
lane 12). Since the Hep-2 domain of pFN gave only 40K and 
30K fragments (Fig. 4E, lane IO), the 35-32K fragment ap- 
pears to be unique to cFNs.  These  results indicate that  the 
structure of the Hep-2 domain is significantly different among 
pFN, N-cFN, and T-cFN. 
Trypsin Digestion-Gross domain structure of these  three 
FNs was compared further by trypsin digestion (Fig. 5). Mild 
trypsin digestion of pFN produced four major fragments, 
215K, 185K, 37K, and 32K (Fig. 5A, lane 4) .  Immunostaining 
with  a  panel of domain-specific antibodies showed that  the 
32K fragment was derived from the NH2-terminal Hep-l/Fib- 
1 domain (Fig. 5B, lane 4 ) ,  whereas the 37K fragment was 
from the COOH-terminal Fib-2 domain (Fig. 5F, lane 4) .  Both 
215K and 185K fragments contained the internal Gel and 
Cell/Hep-2 domains (Fig. 5, C-E, lane 4) .  The 215K, but not 
the 185K, fragment also contained the Fib-2 domain (Fig. 5F, 
lane 4) .  These  results are in good agreement with the previous 
finding (22,36)  that  the 185K and 37K fragments  are derived 
from the (Y subunit, whereas the 215K fragment is from the 
subunit of pFN (see also Fig. 1B). 
The 215K and 185K fragments were further degraded to 
145K, 115K, and 80K fragments at  higher trypsin  concentra- 
tion (Fig. 5A, lane 7). Both the 145K and 115K fragments 
were immunostained by IST-1  and  IST-4 antibodies, but  not 
by anti-Gel antibodies (Fig.  5, C-E, lane 7). The 145K frag- 
ment,  but  not  the 115K fragment, was also stained by anti- 
Fib-2  antibodies (Fig. 5F, lane 7). In contrast, the 80K frag- 
ment was stained only by anti-Gel antibodies (Fig. 5C, lane 
7). These  results  indicate that  the 215K and 185K fragments 
were degraded to  the 145K and 115K fragments, respectively, 
upon release of the Gel domain as  the 80K fragment. 
Mild trypsin digestion of both N-cFN and  T-cFN also gave 
four major fragments, 210K, 165K, 37K, and 32K (Fig. 5A, 
lanes 5 and 6). The 210K and 165K fragments derived from 
T-cFN were slightly larger than those from N-cFN. Immu- 
nostaining with domain-specific antibodies showed that  the 
32K fragment was derived from the  Hep-l/Fib-1 domain (Fig. 
5B, lanes 5 and 6), and  the 37K fragment was derived from 
the Fib-2 domain (Fig. 5F, lanes 5 and 6), as was the case for 
pFN. A 43K fragment that was barely detectable by protein 
staining was also identified by anti-Fib-2  antibodies in  the 
trypsin digests of all three FNs (Fig. 5F, lanes 4-9). This 
fragment may be a precursor form of the 37K fragment or 
may reflect a minor polymorphism in the Fib-2 domain. 
Neither the 210K nor 165K fragment was immunostained by 
anti-Hep-l/Fib-1 or anti-Fib-2 antibodies. Instead,  both were 
stained by anti-Gel and IST-4  antibodies (Fig. 5, C and D, 
lanes 5 and 6). The 210K fragment, but  not  the 165K frag- 
ment, was also stained by IST-1 (Fig. 5E, lanes 5 and 6). IST- 
1 also stained multiple 58-64K fragments. These  results sug- 
gest that  the 210K fragment degrades into  the 165K fragment 
upon release of the Hep-2 domain as 58-64K fragments. The 
Structural  Comparison of Plasma  nd Cellular Fibronectins 5109 
0' 5' 30' 4h 0' 5' ~ _ z c  30' 4h 0 5' 30' 4h . 




1 4 5  
-105 
-60 + 60 
c 44  -44 
1 2  3 4  5 6 7 8  9101112 1 2 3 4 5  6 7 8 9 1 0 1 1 1 2  1  2 3 4 5 6 7  8 91011  12 













1  2 3 4 5 6 7  8 91011 12 1  2 3 4  5 6 7 8  9101112 1 2  3 4 5 6  7 8 9101112 
FIG. 4. Immunoblot analysis of the thermolysin fragments of three  different FNs. FNs (100 pg)  were 
digested with thermolysin (2.5 pg/ml) in 1 ml of 20 mM Tris . C1 (pH 7.8) containing 1.9 mM CAPS, 50 mM NaCl, 
0.5 mM EDTA, and 2.5 mM CaClz at  22 "C for 0 min (lanes 1 3 ) ,  5 min (lanes 4-6), 30 min (lanes 7-9), and 4 h 
(lanes 10-12). The enzyme/substrate  ratio was 1:40. Digestion was terminated by the addition of EDTA to give a 
final  concentration of 5 mM. Five micrograms of protein were applied to lanes 1-3 and 10 pg to lanes 4-12. Lanes 
1, 4, 7, and 10, pFN; lanes 2, 5, 8, and 11, N-cFN, lanes 3, 6,  9, and 12, T-cFN. A ,  protein staining of the gel with 
Coomassie blue; B through F, immunostaining of the nitrocellulose blots with anti-Hep-l/Fib-I (B) ,  anti-Gel (C), 
IST-4 (D), IST-1 (E) ,  and anti-Fib-2 (F) antibodies. Molecular weights of the fragments of interest  are shown in 
the right margin of each panel. 
210K fragment appears to correspond to  the 185K fragment 
of pFN, because these  fragments  share the same internal Gel, 
Cell, and Hep-2 domains. Since the Gel and Cell domains of 
pFN  and  the two cFNs were obtained as similar 44K/60K 
and 105K fragments, respectively, the difference between pFN 
and  the  cFNs  appears  to be in the Hep-2 domain. 
Cathepsin D Digestion-Cathepsin D has been shown to 
release the COOH-terminal region of pFN by retaining the 
interchain disulfide bond(s) (23). Short  cathepsin D digestion 
of pFN produced three fragments, 200K, 70K, and 60K, 
among which the  latter two fragments were  weakly detectable 
by protein  staining (Fig. 6A, lane 4). The 200K fragment was 
immunostained by anti-Hep-l/Fib-1, anti-Gel, and IST-4 an- 
tibodies, but  not by IST-1 nor  anti-Fib-2 antibodies (Fig. 6, 
B-F,  lune 4). Conversely, the 70K and 60K fragments were 
stained by IST-1  and anti-Fib-2 antibodies, but  not by anti- 
Hep-l/Fib-1, anti-Gel, nor IST-4 antibodies (Fig. 6,  B-F, lane 
4) .  The 70K and 60K fragments were either connected to each 
other or to  the uncleaved subunit  chain by disulfide bond(s) 
(23) (data  not shown) and  they  appear to correspond to  the 
75K and 65K cathepsin D fragments reported previously by 
Richter et al. (23) to be derived from the COOH-terminal 
region of pFN. 
In contrast,  the COOH-terminal region of both N-cFN and 
T-cFN gave  much larger fragments than  the 70K/60K frag- 
ments of pFN. Both  IST-1  and  anti-Fib-2 antibodies specifi- 
cally stained  a lOOK fragment after  a 3-h digestion (Fig.  6, E 
and  F, lanes 5 and 6), whereas the  NH2-terminal  and  central 
portion of both  cFNs were released as a 200K fragment as 
was the case for pFN (Fig.  6, B-D, lanes 5 and 6). The 200K 
fragment derived from T-cFN migrated slightly above the 
corresponding fragments produced from pFN  and  N-cFN (Fig. 
Prolonged cathepsin D digestion of pFN gave additional 
130K, 90K, and 67K fragments (Fig. 6A, lane 7). The 67K 
fragment was immunostained by anti-Hep-l/Fib-1  and  anti- 
Gel antibodies (Fig. 6, B  and c, lane 7), indicating that  this 
fragment represents the NH2-terminal region of pFN. The 
130K and 90K fragments were stained by IST-4 antibody 
(Fig.  6D, lane 7). These results indicate that  the 200K frag- 
ment generated at  the early phase of cathepsin D digestion 
was degraded to the NH2-terminal 67K and central 130K 
fragments upon prolonged digestion, whereas the 130K frag- 
ment was further degraded into  a 90K fragment. 
Prolonged cathepsin D digestion of N-cFN and T-cFN 
produced additional 74-83K fragments reactive with IST-1 
6, A-C, lanes 4-6). 
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FIG. 5.  Immunoblot analysis of the  tryptic  fragments of  three  different FNs. FNs (100  pg)  were  digested 
with different concentrations of trypsin  in 20 mM Tris.Cl  (pH 7.8) containing 1.9 mM CAPS, 50 mM NaCl, and 
0.5 mM EDTA at  22 “C for 10 min. Digestion was terminated by the addition of soybean trypsin  inhibitor to give 
a  final concentration of 2.5 pg/ml. Trypsin  concentrations used were: 0 pg/ml (lanes 1-3), 1 pg/ml (lanes 4-6), and 
10 pg/ml (lanes 7-9). Ten micrograms of protein were applied to each lane. Lanes 1,4,  and 7, pFN; lanes 2,5,  and 
8, N-cFN; lanes 3,6,  and 9, T-cFN. A, protein staining of the gel; B through F, immunostaining of the nitrocellulose 
blots with anti-Hep-l/Fib-1 ( B ) ,  anti-Gel (C), IST-4 (D), IST-1 (E) ,  and anti-Fib-2 (F) antibodies. 
and anti-Fib-2 antibodies (Fig. 6, E and F, lanes 8 and 9). 
These fragments often gave a broad band upon immunostain- 
ing, but appeared to consist of two fragments with approxi- 
mately M,  = 74,000 and 83,000. The NH2-terminal  portion of 
both  cFNs was released after prolonged digestion as a 67K 
fragment, which was strongly reactive with anti-Hep-l/Fib-1 
and anti-Gel antibodies (Fig. 6, B and C, lanes 8 and 9). 
Longer digestion of cFNs also produced 130K and 90K frag- 
ments which  were  recognized  by the IST-4 antibody (Fig. 6, 
0, lunes 8 and 9). These results indicate that the NHz- 
terminal  and  central regions of cFNs are very similar, if not 
identical, to  that of pFN, whereas the COOH-terminal region 
of both cFNs was significantly larger than that of pFN. 
However, there was no clear difference between N-cFN and 
T-cFN even at the COOH-terminal region. 
S-Cyunylution-A difference in  the COOH-terminal region 
of pFN  and  cFNs was further  demonstrated by S-cyanylation. 
S-Cyanylation of human pFN has been shown to produce 
three major fragments, sclGOK, sc135K, and sc125K (33,34) 
(also see Figs. 1D  and 7A, lane 1). The scl6OK represents the 
NHz-terminal half of both a and p subunits  as revealed  by 
specific immunostaining with anti-Hep-IIFib-1  and anti-Gel 
antibodies (33) (Fig. 7, B and C, lune 1). The sc135K and 
125K fragments represent  the COOH-terminal halves of the 
CY and /3 subunits (33) and were immunostained by anti-Fib-2 
antibodies (Fig. 70, lane 1). 
S-Cyanylation of both N-cFN and  T-cFN apparently pro- 
duced only one major fragment with M ,  = 155,000  (Fig. 7A, 
lanes 2 and 3).  Immunostaining with anti-Hep-1IFib-1 and 
anti-Gel antibodies detected a sc155K fragment as  the  NH2- 
terminal half of both  cFNs (Fig.  7, B and C, lunes 2  and 3) .  
The COOH-terminal half of N-cFN, however,  was identified 
by anti-Fib-2 antibodies as  a broad 160-145K band (Fig. 70, 
lane 2). Although the resolution of the closely spaced bands 
on  the autoradiogram was limited, the COOH-terminal half 
of N-cFN appears to consist of two discrete bands, scl6OK 
and sc145K. This may indicate that N-cFN consists of two 
nonidentical subunit  chains (see also under “Discussion”). In 
contrast,  the COOH-terminal half of T-cFN gave a scl6OK 
fragment, but almost no sc145K fragment, stainable by anti- 
Fib-2 antibodies (Fig. 70, lune 3).  
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FIG. 6. Immunoblot analysis of cathepsin D fragments of three different FNs. FNs (80 pg)  were digested 
with cathepsin D at an enzyme/substrate ratio of  1:250 in 1 ml of  50 mM sodium acetate (pH 3.5) containing 1.8 
mM CAPS, 0.5 mM EDTA, and 0.2 mM phenylmethylsulfonyl fluoride at  37 "C for 0 h (lunes 1 3 ) ,  3  h (lanes 4-6), 
and 18 h (lanes 7-9). Digestion was terminated by the addition of 10 times molar excess of pepstatin A and 28 pl 
of 2.5 M Tris. C1 (pH 8.8) to bring the  pH  to approximately 7.5. Five micrograms of protein were applied to lanes 
1-3 and 7.5 pg to lanes 4-9. Lunes I ,  4, and 7, pFN; lanes 2, 5, and 8, N-cFN, lanes 3, 6, and 9, T-cFN. A,  the 
protein  staining of the gel; B through F, show the immunostaining of the nitrocellulose blots with anti-Hep-l/Fib- 
1 ( B ) ,  anti-Gel (C) ,  IST-4 (D), IST-1 (E) ,  and anti-Fib-2 (F) antibodies. The small double arrows in B indicate the 





The domain structure of three different FNs,  pFN, N-cFN, 
and T-cFN, was compared by limited proteolysis and S- 
cyanylation followed by identification of each domain by a 
panel of domain-specific antibodies. This approach is highly 
sensitive, specific, and capable of picking up small quantities 
of fragments derived from specific domains. Fig. 8 shows a 
proposed model of the domain structure of cFNs  and  their 
fragmentation patterns upon proteolytic and chemical deg- 
radation. The corresponding patterns of pFN, based on pre- 
vious studies (13, 22-24, 33-37), are shown in Fig. 1. The 
results  indicate clearly that  the overall composition and align- 
ment of the functional  domains of all three  FNs  are essentially 
identical. However, one major difference between pFN  and 
the two cFNs was found at  the COOH-terminal region, i.e., 
the Hep-2 domain, detectable by monoclonal antibody IST-1. 
Although the differences between N-cFN and T-cFN were 
minor, a clear distinction  in the thermolysin fragments rep- 
resenting the Gel and Hep-2 domains and in the tryptic 
fragments  representing internal domains were  observed. 
Difference between pFN and cFNs"Severa1 lines of evi- 
dence indicate that  the region showing the major difference 
between pFN  and  cFNs i localized within the Hep-2 domain. 
(i) Limited proteolysis with thermolysin and trypsin showed 
that  pFN  and both cFNs consist of almost identical Hep-I/ 
Fib-1, Gel,  Cell, and Fib-2 domains. However, the thermolysin 
fragments  representing the Hep-2 domain of pFN were clearly 
different from those of cFNs. The Hep-2 domain of cFNs, 
identified by IST-1 antibody, gave a characteristic 35-32K 
fragment, whereas the same domain of pFN was obtained as 
40K and 30K fragments. (ii) The COOH-terminal Hep-2 and 
Fib-2  domains of pFN were released by cathepsin D as 70K 
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FIG. 7. Immunoblot analysis of S-cyanylation fragments of 
three different  FNs. FNs (200 pg)  were S-cyanylated with 0.5 mM 
2-nitro-5-thiocyanobenzoic acid in 1 ml of 0.1 M Tris/acetate (pH 
8.0) containing 0.5 mM EDTA and 0.1% SDS. The modified FNs 
were dialyzed against 20 mM Tris/acetate (pH 9.0) containing 0.1 mM 
EDTA and 0.1% SDS for the cleavage. The cleaved FNs were dialyzed 
against 10 mM Tris.Cl  (pH 7.0) containing 0.5 mM EDTA, lyophi- 
lized, and subjected to immunoblot analysis. Lane l ,  pFN; lune 2, N- 
cFN; lane 3, T-cFN. A, the protein  staining of the gel; B through D, 
the immunostaining with anti-Hep-l/Fib-1 (B) ,  anti-Gel (C) ,  and 
anti-Fib-2 (D) antibodies. Twelve micrograms of protein were applied 
to each lane. The small double arrows in B indicate the contaminant 
tryptic 32K fragment  in the purified pFN. 
and 60K fragments  (23), whereas the same region of both  N- 
cFN and  T-cFN was obtained as lOOK and 83K-74K frag- 
ments by cathepsin D digestion. Since there was no significant 
difference in the Fib-2 domain between pFN  and cFNs, the 
difference in  the cathepsin D-derived, COOH-terminal frag- 
ments could be mapped to  the Hep-2 domain. Thus,  the Hep- 
2 domain of cFNs appears to be  30,000-20,000 daltons larger 
than  the Hep-2 domain of pFN. In  support of this conclusion, 




the major Hep-2 derived fragments  obtained from pFN  and 
cFNs by tryptic digestion or S-cyanylation also showed clear 
differences. The Hep-2 domain of cFNs was recovered within 
a 210K fragment, which spans from the Gel through the Hep- 
2 domain, upon mild trypsin digestion. The corresponding 
region of pFN was released as a 185K fragment. The COOH- 
terminal half of cFNs, including Hep-2,  Fib-2, and a part of 
Cell domains, was obtained as sc160K-145K fragments upon 
S-cyanylation, whereas the corresponding COOH-terminal 
half of pFN was obtained as sc135K/125K fragments. 
Conversely, the NHz-terminal half of cFNs (the sc155K 
fragment) was approximately 5,000 daltons smaller than  the 
NH2-terminal half of pFN  (the scl6OK fragment). This dif- 
ference may be attributable  to differences in the carbohydrate 
moieties, which have been shown to cluster in the NHz- 
terminal half (35). Similarly, the 44K/60K thermolysin frag- 
ments derived from the Gel domain showed a  small difference 
in electrophoretic mobility between pFN and N-cFN; the 
44K/60K fragments of N-cFN, but not T-cFN, appeared to 
be slightly smaller than those of pFN. A similar difference 
has been observed between chicken pFN  and  cFN (37). 
Previously, Hayashi and Yamada (37) compared the poly- 
peptide structure of chicken pFN  and cFN by limited prote- 
olysis with thermolysin followed by fractionation of the re- 
sulting  fragments  on various affinity columns. Three regions 
showed differences between pFN and cFN. One difference 
was in  the Gel domain and  the  other two differences were in 
the Cell/Hep-2 domain where pFN had an 11,000-dalton 
deletion in one site  and a 1,000-dalton extrasegment  in the 
other  site (37). These authors mapped the 11K deletion site 
in  pFN  at  the NHz-terminal region of the CeZl/Hep-2 domain. 
Our data, however, strongly suggest that  the major deletion 
site in  human pFN is in the COOH-terminal region of the 
domain, i.e., Hep-2. This apparent discrepancy may be the 
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FIG. 8. A proposed model for the domain structure of  cFNs and their fragmentation patterns. The 
corresponding model for pFN is shown in Fig. 1. The ( Y )  attached to  intact FNs (center) represents the carbohydrate 
units  attached to polypeptide chains. Small arrows (JJ) indicate the multiple cleavage sites, which generate several 
fragments with slightly different molecular weights. ( N )  and (2') stand for N-cFN and  T-cFN, respectively. (T > 
N )  indicates that  the fragments derived from T-cFN are slightly larger than those from N-cFN. 
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Alternatively,  the topological mapping of the  fragments based 
on  their  binding specificities to  various ligands may not  be 
exclusive of other possibilities, since  there  are  multiple  bind- 
ing  sites  in  FNs  for  heparin, DNA, and Staphylococcus aureus 
(37);  mapping of the  1lK deletion  site  in  chicken  pFN was 
based essentially  on  the  binding of thermolysin  fragments  to 
these ligands.  A structural difference near  the  COOH-termi- 
nal  end between pFN  and  cFN  has  also been suggested by 
Atherton  and  Hynes (38) using  an  anti-FN monoclonal anti- 
body that  preferentially  reacted  with  cFN. 
Recently,  several  groups have reported the isolation of 
cDNA clones for  chicken,  human,  and  rat  FNs (39-43). 
Schwarzbauer et al. (42) reported that rat liver contained 
three different mRNAs, among which two shorter mRNAs 
had 75 and 360 base deletions  within  the region encoding  the 
COOH-terminal  heparin-binding  domain.  These  findings  are 
consistent with our present observations. Kornblihtt et al. 
(43)  also  found two different  mRNAs  in  human  breast  carci- 
noma cells; one of them  had a deletion of 270 bases  in  the 
region encoding  the  Hep-2  domain.  This 270 nucleotide se- 
quence was found to correspond to the so-called "type 111 
homology" which is  repeated more than six times  in  the Cell/ 
Hep-2  domain (44, 45). 
Differences between N-cFN and T-cFN-In spite of the 
clear difference  between pFN  and  cFNs described  above, the 
domain  fragments released from  N-cFN  and  T-cFN defined 
by antibodies to Hep-1/Fib-1, Gel, and Fib-2 domains were 
essentially identical. There was, however, a clear difference 
between N-cFN  and  T-cFN  in  the  Hep-2  domain defined by 
the  IST-1  antibody, i.e., three  fragments  (40K, 35-32K3, and 
30K) were released from N-cFN, while only the 35-32K 
fragment was released  from T-cFN  on  extensive  thermolysin 
digestion. In addition, the following minor differences be- 
tween N-cFN  and  T-cFN  in size of domain  fragments were 
observed. (i) The 44K/60K Gel domain fragments from T -  
cFN were consistently larger than  those  from  N-cFN;  (ii)  the 
tryptic 210K and 165K fragments of T-cFN were slightly 
larger  than  those of N-cFN;  (iii)  the 200K cathepsin D frag- 
ment of T-cFN was slightly  larger  than  that of N-cFN;  and 
(iv) the COOH-terminal half of N-cFN was obtained as a 
mixture of scl6OK and sc145K fragments,  whereas  the 
COOH-terminal half of T-cFN was obtained  only as a scl6OK 
fragment.  Since  human  carcinoma cells have been  shown to 
contain two different FN mRNAs  (43),  the scl6OK and 
sc145K fragments of N-cFN may represent  the  COOH-ter- 
minal halves of two different  subunit polypeptides. The  struc- 
tural basis for the differences between N-cFN and T-cFN 
described  above is unknown.  It may well be due  to  the degree 
of phosphorylation (20) and  to differences in carbohydrate 
structure detectable between N-cFN and T-cFN (21). Al- 
though glycosylation  occurs  densely at   the Gel domain (35), 
it also  occurs in  the  COOH-terminal half.3 Further  extensive 
study in domain distribution of carbohydrates is obviously 
important  to clarify the  domain  polymorphism of the various 
cFNs and their matrix forms. These differences in post- 
translational modification  may  have important functional 
significance. 
The  FN  produced by cultured  fibroblasts is partly  deposited 
in  the  pericellular  matrix  and  partly released into  the  culture 
medium. Recently, we analyzed  the  domain  structure of the 
cFN  in  the  pericellular  matrix of normal  human  fibroblasts 
(33).  The  proteolytic  and chemical fragmentation profiles of 
the  matrix  form of cFN were very similar  to  those of released 
form of cFN  reported here. Further  detailed  studies  are needed 
E. Nichols and S. Hakomori,  unpublished  observation. 
to  substantiate  the  identity of matrix form and released  form 
of cFN. It  is possible, however, that  matrix form and released 
form of cFNs  share  the  same polypeptide structure,  but differ 
in their degree of disulfide bond-dependent polymerization 
(17-19). I t  should  be  noted  that  the  cFNs o far analyzed  for 
domain  structure were all produced in vitro by cultured fibro- 
blasts,  whereas  pFN was obviously produced in vivo, probably 
by liver  cells (46,47).  It will be important  to  study  tissue  FN; 
however, it  has been  difficult to  obtain  tissue  FN  in  an  intact 
form. The protocol  used in  the  present  study does not require 
purification of these  proteins  and  has  been successfully ap- 
plied to the structural analysis of cFN in the pericellular 
matrix (33). The  same  method  should be applicable for the 
analysis of cFN  in tissue. 
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